Tango Therapeutics, Inc.
TNGX
$1.28
-$0.095-6.91%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -64.53% | -41.60% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -64.53% | -41.60% | |||
| Cost of Revenue | 2.03% | -13.95% | |||
| Gross Profit | -37.70% | -15.32% | |||
| SG&A Expenses | -1.18% | 4.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.22% | -10.00% | |||
| Operating Income | -24.43% | -11.25% | |||
| Income Before Tax | -29.22% | -14.23% | |||
| Income Tax Expenses | -9.26% | -16.92% | |||
| Earnings from Continuing Operations | -29.15% | -14.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -29.15% | -14.15% | |||
| EBIT | -24.43% | -11.25% | |||
| EBITDA | -24.91% | -11.54% | |||
| EPS Basic | -28.94% | -13.95% | |||
| Normalized Basic EPS | -16.10% | -14.00% | |||
| EPS Diluted | -28.94% | -13.95% | |||
| Normalized Diluted EPS | -16.10% | -14.00% | |||
| Average Basic Shares Outstanding | 0.16% | 0.18% | |||
| Average Diluted Shares Outstanding | 0.16% | 0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||